Hematopoietic Stem Cell TransplantationTransplantation, HomologousTransplantation ConditioningGraft vs Host DiseaseBone Marrow TransplantationHematologic NeoplasmsMyeloablative AgonistsHistocompatibilityWhole-Body IrradiationTissue DonorsHistocompatibility TestingUnrelated DonorsBone MarrowTransplantation ChimeraTransplantation, AutologousGraft vs Leukemia EffectLeukemiaGraft vs Tumor EffectBone Marrow CellsGraft SurvivalTreatment OutcomeHLA AntigensPeripheral Blood Stem Cell TransplantationLeukemia, Myeloid, AcuteVidarabineRecurrenceCord Blood Stem Cell TransplantationRetrospective StudiesSiblingsImmunosuppressive AgentsStem Cell TransplantationBusulfanChimerismSurvival AnalysisRemission InductionMyelodysplastic SyndromesSurvival RateDisease-Free SurvivalLymphocyte DepletionPrecursor Cell Lymphoblastic Leukemia-LymphomaGraft RejectionDonor SelectionMinor Histocompatibility AntigensT-LymphocytesHematologic DiseasesAcute DiseaseCyclosporineSevere Combined ImmunodeficiencyHematopoietic Stem CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTime FactorsImmunosuppressionLiving DonorsBone and BonesAllograftsFollow-Up StudiesCyclophosphamideCombined Modality TherapyAnemia, AplasticCytomegalovirus InfectionsHaploidyKidney TransplantationLymphoma, Non-HodgkinLymphocyte TransfusionHaplotypesLiver TransplantationAntilymphocyte SerumMycophenolic AcidRisk FactorsHematopoiesisLymphoproliferative DisordersReceptors, KIRTacrolimusChronic DiseaseFetal TherapiesLymphomaMice, Inbred C57BLAntigens, CD34MycosesSalvage TherapyPrognosisTransplantation ImmunologyTransplantationTransplantation, IsogeneicMultiple MyelomaAge FactorsCell TransplantationAntineoplastic AgentsHeart TransplantationHepatic Veno-Occlusive DiseaseCohort StudiesImmunocompromised HostKiller Cells, NaturalBone Marrow PurgingProspective StudiesIncidenceCytomegalovirusBone Marrow DiseasesOpportunistic InfectionsCD8-Positive T-Lymphocytes